Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura

D.Z. Edelmann¹,², B. Knobel²,³, I. Virag¹ and D. Meytes¹,³

Departments of ¹Hematology and ²Medicine ‘B’, The Edith Wolfson Medical Center, Holon 58100, and ³The Sackler Faculty of Medicine, Tel-Aviv University, Israel

Summary: Seven non-splenectomized patients with chronic refractory idiopathic thrombocytopenic purpura were treated with danazol 800 mg daily. All were glucocorticoid failures and four were refractory to all additional previous therapy. Five patients benefited from danazol and in two sustained normal platelet counts, for over 44 and 51 months, were observed. We conclude that danazol is useful for long term management of otherwise refractory idiopathic thrombocytopenic purpura. The advantage of danazol over splenectomy as a first line treatment in steroid failure is suggested.

Introduction

Thrombocytopenia in most patients with idiopathic thrombocytopenic purpura (ITP) responds to steroids.¹,²–⁵ Splenectomy is considered the treatment of choice in steroid failures,¹,⁴,⁵ followed by immunosuppressive therapy when needed.¹,² Danazol, a derivative of ethinyl testosterone, is a synthetic attenuated androgen with reduced masculinizing capacity, initially formulated for the treatment of endometriosis.²,³,⁶–⁸ Favourable results of danazol therapy in refractory ITP were first described by Ahn et al. in 1983.⁶ In the few reports published since, the authors were almost equally divided between those who achieved similar results⁸–¹⁰ and those who failed to show a significant response.³,¹¹ Since splenectomy may have operative and in particular considerable post-operative complications, we considered it worthwhile to examine the effect of danazol in patients with ITP, prior to splenectomy.

Materials and methods

Seven patients with chronic refractory ITP, who refused splenectomy, were studied. Patients’ data and treatment regimen before danazol are presented in Table I. Six were steroid failures and in one steroids were contraindicated. In five patients a daily dose of prednisone (60–150 mg), during at least 6 weeks, failed to raise platelet counts to adequate levels. In one patient (No. 5) although a transient response, up to 142 × 10⁹/l platelets, was noted, steroid withdrawal was associated with a decline in platelet counts and bleeding. The addition of immunosuppressive therapy in five patients failed to raise platelet counts.

All patients were treated with a fixed dose of danazol (Danocrine®, Winthrop) 800 mg daily for at least 3 months. Evaluation of response was scaled as follows: ‘excellent’ – when platelet count rose to 100 × 10⁹/l or more and remained there for at least 2 months with continued therapy; ‘good’ – a sustained increase to 50–100 × 10⁹/l; ‘transient’ – when the rise was to more than 50 × 10⁹/l and lasted less than 2 months; ‘poor’ – when platelet counts did not rise over 20 × 10⁹/l.

Results

Results of treatment with danazol are presented in Table II. Five of the seven patients improved under danazol. Three had ‘excellent’, one ‘good’ and one a ‘transient’ response. Two of the excellent responders (Nos 1, 3) have maintained their platelet counts above 100 × 10⁹/l for 44 and 51 months, with danazol being the only treatment. In patient No. 1 the discontinuation of danazol was associated with a significant reduction of platelet counts, while readministration was repeatedly followed by a rise to normal values. In patient No. 7 after 3 months of treatment with an excellent response the dose of danazol was reduced and platelet count declined to 30 × 10⁹/l. This value was higher than the one previously observed with prednisone and azathioprine combined. Synergistic effect of prednisone and danazol was noted in the good responder (No. 6), in whom prednisone was reduced from 30 mg daily prior to danazol therapy to 10 mg when the two drugs were given.

Correspondence: D. Meytes, M.D.
Accepted: 9 May 1990
simultaneously. In this patient there was a 7-fold elevation in platelet count. This patient was the only one who suffered from side effects of danazol. He had headache and nausea which caused cessation of treatment. One patient exhibited a 'transient' response though danazol was continued. Maximal response was seen within one month of treatment in three of the five responders. No response was noted in two patients.

**Discussion**

The potential therapeutic modalities available for patients with ITP who do not respond to steroids are far from being satisfactory.

Immunosuppressive drugs such as vinca alkaloids, cyclophosphamide and azathioprine have been shown to produce a rise in platelet counts in some patients. However, side effects, mainly bone marrow suppression and sterility, together with the short lived effect of vinca alkaloids and the carcinogenic potential of cyclophosphamide and azathioprine are major disadvantages. Splenectomy, besides having operative and post-operative hazards does not benefit all patients. High dose intravenous immunoglobulin IgG is very expensive and only of temporary effect.

Danazol for refractory ITP was first introduced in 1983 by Ahn et al. with encouraging results. Sixteen out of 22 patients (68%) were improved and in 11 (50%) sustained normal platelet counts for 2–3 months were recorded. These results seemed especially promising, as danazol has been utilized for the management of many non-haematological disorders in the last 15 years without significant side effects. 

The mechanism of danazol activity in ITP is not clear. Animal experiments suggest that it reduces antibody secretion by enhancing the function of suppressor cells, but the study of the effect of danazol on the level of antiplatelet antibodies in patients with autoimmune thrombocytopenia has yielded conflicting results. Danazol also suppresses macrophage activity and may mediate its clinical effect at least in part by decreasing the number of available Fc (IgG) receptors on human monocytes. It appears to be an effective immune modulator which increases T helper/inducer cells in patients with autoimmune thrombocytopenia.

The results of clinical studies following the first report are inconsistent (Table III). In two, a beneficial effect was seen: in one, all three patients demonstrated various degrees of response; in the other, 7 out of 14 patients (50%) responded and 5 had a sustained complete remission.

---

**Table I** Patients' data and treatment regimens prior to danazol therapy

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yrs)</th>
<th>Sex</th>
<th>Duration of ITP prior to danazol (months)</th>
<th>Steroids</th>
<th>Previous treatment</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>62</td>
<td>F</td>
<td>235</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>84</td>
<td>M</td>
<td>180</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>72</td>
<td>F</td>
<td>49</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>55</td>
<td>F</td>
<td>38</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>61</td>
<td>M</td>
<td>13</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>55</td>
<td>M</td>
<td>4</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>62</td>
<td>F</td>
<td>12</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**Table II** Results of danazol therapy in idiopathic thrombocytopenic purpura

<table>
<thead>
<tr>
<th>Patient</th>
<th>Platelet count (x 10^9/l)</th>
<th>Duration of follow up (months)</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
<td>92</td>
<td>44</td>
</tr>
<tr>
<td>2</td>
<td>18</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>16</td>
<td>25</td>
<td>51</td>
</tr>
<tr>
<td>4</td>
<td>23</td>
<td>55</td>
<td>50</td>
</tr>
<tr>
<td>5</td>
<td>11</td>
<td>16</td>
<td>8.5</td>
</tr>
<tr>
<td>6*</td>
<td>9</td>
<td>65</td>
<td>40</td>
</tr>
<tr>
<td>7</td>
<td>15</td>
<td>114</td>
<td>15</td>
</tr>
</tbody>
</table>

*Patient stopped danazol because of side effects; †see text for explanation.
In contrast, in two other studies results were much less encouraging. In one study only one out of 10 patients had a sustained increase in platelet counts and two others had transient response; in the second, only one single patient out of 9 showed long-term normalization of platelet counts while in another a transient response was noted. The reason for the different results is not clear. Whether different patient populations or differences in danazol dosage, which was not uniform for all patients reported, cause the discrepant results, cannot be determined. Our data, although based on a small group of patients, are in accordance with those of Ahn et al. and also show various degrees of improvement in 5/7 of the patients. Moreover, in all previous studies the majority of the patients were splenectomized. Clinical experience with danazol in non-splenectomized patients has been very limited so far.

Danazol was found useful in the treatment of refractory autoimmune thrombocytopenia associated with systemic lupus erythematosus and in all 6 patients thrombocytopenia resolved within 6 weeks of the addition of danazol to the previously existing medications. For two of the patients glucocorticoids had failed, for one patient glucocorticoids and azathioprine had failed, for another glucocorticoids and splenectomy had failed and for the remaining two patients glucocorticoids, splenectomy and azathioprine had been unhelpful.

The effectiveness of danazol in steroid resistant patients on the one hand and its safety on the other, raises the possibility that this drug should be considered among the first line therapeutic modalities available for the treatment of ITP. Its introduction before splenectomy and/or immunosuppressives may be not infrequently associated with favourable results and might save splenectomy in many patients. The optimal doses for induction of response and for its maintenance, as well as the duration of therapy remain to be determined in future controlled studies in a larger group of ITP patients.

References


Table III Data from published studies using danazol for the treatment of idiopathic thrombocytopenic purpura

<table>
<thead>
<tr>
<th>Author</th>
<th>Danazol dosage mg/day</th>
<th>No. of splenectomized patients/total no. of patients</th>
<th>Results* no. of benefited patients/total no. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahn²</td>
<td>400–800</td>
<td>15/22</td>
<td>Favourable 15/22</td>
</tr>
<tr>
<td>Mcvery²</td>
<td>600</td>
<td>6/10</td>
<td>Non-favourable 3/10</td>
</tr>
<tr>
<td>Heyd⁵</td>
<td>800</td>
<td>3/3⁵</td>
<td>Favourable 3/3</td>
</tr>
<tr>
<td>Buelli⁹</td>
<td>600</td>
<td>6/14</td>
<td>Favourable 7/14</td>
</tr>
<tr>
<td>Almagro¹⁰</td>
<td>400–800</td>
<td>1¹</td>
<td>Non-favourable 2/9</td>
</tr>
</tbody>
</table>

*Favourable – 50% or more response rate; non-favourable – 30% or less response rate. ¹One patient underwent splenectomy after secondary danazol failure. ²No data on the number of patients who underwent splenectomy before danazol.


Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura.

D. Z. Edelmann, B. Knobel, I. Virag and D. Meytes

doi: 10.1136/pgmj.66.780.827

Updated information and services can be found at:
http://pmj.bmj.com/content/66/780/827

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/